Skip to content

Therapeutic effect of Tofacitinib on skin amyloidosis

Therapeutic effect of Tofacitinib on skin amyloidosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100067
Enrollment
Unknown
Registered
2025-04-02
Start date
2024-04-25
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary cutaneous amyloidosis

Interventions

Experimental group:Tofacitinib 5mg bid

Sponsors

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patient is between 18-65 years old; 2. The skin lesions meet the clinical diagnostic criteria for LA and MA; 3. After pathological examination, it meets the pathological diagnostic criteria of PCA: that is, uniform and unstructured eosinophilic substances are seen in HE staining, and metachromatic reaction is seen in crystal violet staining, which is purple-red; 4. No use of corticosteroids, immunosuppressants and JAK inhibitors, such as baricitinib and abuxitinib, in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Other types of cutaneous amyloidosis; 2. Pregnant and lactating women; 3. Have had a severe allergic reaction, or have a known allergy to JAK inhibitors; 4. Severe neurological and psychiatric diseases, endocrine and metabolic system diseases, connective tissue diseases; 5. History of major surgery in the past 8 weeks, infection in the past 12 weeks, mainly including bacterial and viral infections, such as lung infection, shingles, chickenpox, erysipelas and cellularity, etc.; 6. Suffering from hematologic diseases, such as myelodysplastic syndrome, trilineage hypoplasia, etc.; 7. Positive for hepatitis B surface antigen and HBV-DNA; 9. Evidence of latent tuberculosis or active tuberculosis, including evidence of tuberculosis on lung CT, positive T-SPOT, etc.; 9. Suffering from malignant neoplastic diseases; 10. Severe hepatic and renal insufficiency; 11. Have a history of drug abuse, alcoholism, or drug abuse.

Design outcomes

Primary

MeasureTime frame
Extent of lesions;Pruritus Numeric Rating Scale score;Dermatology quality of life questionnaire results;Lesion severity score;

Countries

China

Contacts

Public ContactCao Yuchun

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

963808187@qq.com+86 189 7160 6517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026